StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
MISTBullishEarningsnews
High materiality8/10

Milestone expands CARDAMYST coverage to 50% of commercial lives; AFib-RVR Phase 3 underway

Aug 12, 2026, 7:15 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Key positive catalysts include a meaningful insurance-coverage expansion for CARDAMYST and a progressing Phase 3 program; these can drive higher adoption and revenue potential, improving unit economics if Phase 3 data or regulatory milestones align with the sNDA pathway. Dilution risk remains from losses, but cash runway extends into 2027.

AI summary

What happened, with direct paths to the underlying reporting

Milestone Pharmaceuticals reports Q2 2026 results with CARDAMYST coverage expanding to over 50% of commercially insured lives, aided by UnitedHealthcare. The company has opened multiple Phase 3 AFib-RVR sites (ReVeRA-301) and expects first patient enrollment in H2 2026, signaling a potential expansion beyond PSVT. Cash and equivalents total $170.6 million, funding operations into 2H 2027 amid ongoing launch costs.

  • CARDAMYST coverage now covers about 50% of commercial lives; insurer formulary expands reach.
  • Phase 3 AFib-RVR ReVeRA-301 trial opened; first patient enrollment targeted in H2 2026.
  • Q2 2026 cash $170.6M; runway into 2H 2027 despite net losses.
  • Q2 product revenue $0.6M; six months $0.8M; SG&A up due to launch activities.
  • 800+ prescribers; 1,500+ CARDAMYST scripts; patient base expanding with new coverage.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event